ASPA rs121907955: Understanding Canavan Disease Carrier Status
The genetic variant rs121907955, located in the ASPA gene, is a well-documented founder mutation known as p.Glu285Ala. It is primarily associated with carrier status for Canavan disease, an autosomal recessive neurodegenerative disorder.
What each genotype means
Typical aspartoacylase enzyme activity
You carry two non-variant copies of this position in the ASPA gene. You do not carry the specific p.Glu285Ala founder variant linked to Canavan disease. Because this test only covers this specific site, it does not rule out other rare changes in the ASPA gene.
Found in the vast majority of all global populations, including over 97% to 98% of individuals of Ashkenazi Jewish ancestry.
Canavan disease carrier
You carry one copy of the pathogenic p.Glu285Ala (c.854A>C) variant, indicating that you are an unaffected genetic carrier for Canavan disease. Carriers typically experience no health symptoms because one functional copy produces adequate enzyme activity. If you are planning a pregnancy, sharing this carrier result with your partner and discussing it with a genetic counselor can clarify reproductive risks.
Carried by approximately 1 in 40 to 1 in 60 individuals of Ashkenazi Jewish ancestry; it is extremely rare in non-Ashkenazi populations.
Severe aspartoacylase deficiency risk
You carry two copies of the pathogenic p.Glu285Ala variant, which causes severe or total deficiency of the aspartoacylase enzyme. Biallelic inheritance of this variant is classically associated with infantile Canavan disease, an autosomal recessive neurodegenerative leukodystrophy. Clinical correlation and consultation with a medical geneticist are essential to evaluate symptoms and management options.
Extremely rare globally, occurring almost exclusively in children whose parents are both carriers of this Ashkenazi Jewish founder allele.
What is rs121907955?
The variant rs121907955 is a specific change in the DNA sequence of the ASPA gene, technically identified as c.854A>C. This mutation results in an amino acid substitution where glutamic acid is replaced by alanine at position 285 of the aspartoacylase protein, often referred to as p.Glu285Ala. This variant is classified as a founder mutation, meaning it is found at a higher frequency in specific populations due to historical demographic factors, such as the expansion of a small ancestral group. In the context of genetic testing, it is one of the primary markers screened for when assessing carrier status for Canavan disease. Because it is a missense mutation, it alters the protein's structure, which can impact its ability to function correctly within the body's cells.
The Role of the ASPA Gene
The ASPA gene provides instructions for producing an enzyme called aspartoacylase. This enzyme is primarily active in the brain, where it is responsible for breaking down a substance known as N-acetylaspartic acid (NAA). NAA is found in high concentrations in the brain, and its proper breakdown is essential for the maintenance of myelin, the protective sheath that insulates nerve fibers and allows for efficient signal transmission. When the ASPA gene contains pathogenic mutations that significantly reduce or eliminate enzyme activity, NAA accumulates to toxic levels. This accumulation is associated with the disruption of myelin and the subsequent spongy degeneration of white matter in the brain, which are the hallmarks of Canavan disease. Understanding this gene's function is critical for recognizing why specific variants can lead to severe neurological outcomes when inherited in a recessive manner.
Research and Clinical Significance
Research has firmly established rs121907955 as a major contributor to the genetic burden of Canavan disease within the Ashkenazi Jewish population. Studies indicate that this specific mutation, along with another common variant, accounts for the vast majority of pathogenic ASPA alleles in this group. Because Canavan disease is an autosomal recessive condition, an individual must inherit two pathogenic variants—one from each parent—to be affected by the disease. Carriers, who possess only one copy of the variant, typically do not exhibit symptoms of the condition. The evidence for this variant's role in disease pathology is strong, leading to its inclusion in standard carrier screening panels. However, it is important to note that while this variant is a primary focus, clinical interpretation should always be handled by a qualified genetic counselor or medical professional who can contextualize the findings within a person's broader health history.
Population Frequency
The frequency of the rs121907955 variant is notably higher in individuals of Ashkenazi Jewish ancestry compared to the general global population. Scientific literature and clinical guidelines consistently cite a carrier frequency for Canavan disease in this population ranging from approximately 1 in 40 to 1 in 82. This elevated frequency is a classic example of a founder effect, where the mutation became more common in a geographically or culturally isolated group over generations. Outside of this specific ancestry, the variant is significantly rarer. Genetic screening programs often prioritize this variant when testing individuals of Ashkenazi Jewish descent to provide accurate reproductive risk assessments. Because these frequencies are estimates based on population studies, they serve as a guide for clinical screening rather than a precise prediction for any single individual.
Navigating Genetic Information
Accessing information about your genetic status can be empowering, but it is essential to understand the limitations of such data. Knowing you are a carrier for a variant like rs121907955 does not mean you have or will develop Canavan disease, as it is a recessive trait. However, this information is highly relevant for family planning, as it informs the potential risk of passing the variant to future children. If you receive a result indicating you are a carrier, the most appropriate next step is to consult with a genetic counselor. They can explain the inheritance patterns, discuss the implications for your family members, and provide guidance on testing options for partners. Never use genetic data to make independent medical decisions or to diagnose yourself. Always rely on professional clinical guidance to interpret how these findings apply to your specific health and reproductive circumstances.
How common is this variant?
The carrier frequency for this variant is approximately 1 in 40 to 1 in 82 within the Ashkenazi Jewish population, where it is considered a founder mutation.
Frequently asked questions
What does it mean to be a carrier for Canavan disease?
Being a carrier means you have one copy of a pathogenic variant in the ASPA gene. Because Canavan disease is recessive, carriers do not have the disease themselves but can pass the variant to their children.
Is rs121907955 the only cause of Canavan disease?
No, there are many different mutations in the ASPA gene that can cause Canavan disease. While rs121907955 is a common founder mutation in the Ashkenazi Jewish population, other rare mutations exist.
Should I get tested for this variant?
Carrier screening is often recommended for individuals of Ashkenazi Jewish descent who are planning a family. You should discuss the benefits and limitations of this testing with a genetic counselor or your primary care physician.
Can I change my genotype for this variant?
No, your genotype is determined at conception and cannot be changed. Genetic testing simply identifies the sequence you were born with.
Sources & further reading
Educational information only, last refreshed 10/17/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121907955?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in ASPA
Pathogenic founder mutation (p.Tyr231Ter) associated with Canavan disease.
Pathogenic missense variant (p.Glu285Ala / E285A) causing aspartoacylase deficiency and carrier status for autosomal recessive Canavan disease.
Common pathogenic nonsense mutation (p.Tyr231Ter) in ASPA underlying Canavan disease.
Severe pathogenic ASPA nonsense mutation (p.Tyr231Ter) responsible for Canavan disease in reproductive carrier screening.
Pathogenic ASPA missense variant (p.Glu285Ala) causing aspartoacylase deficiency (Canavan disease), standardly tested in preconception carrier panels.
A nonsense mutation (c.693C>A, p.Tyr231Ter) in ASPA leading to truncated aspartoacylase and defining carrier status for Canavan disease.